Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,689 recruiting studies in this area right now.
By phase
- Not applicable9,836
- Phase 24,475
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Prostate Cancer659
- Cancer658
- Colorectal Cancer495
- Lung Cancer430
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer298
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma286
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors196
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University312
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,427
- Texas642
- Arizona513
- Florida443
- Alabama421
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania240
Recruiting studies20,689 total
- NCT05746754Recruiting
Proton radiation for cancer spread into the covering of the brain
This trial tests proton radiation to treat cancer that has spread into the thin lining around the brain and/or spinal cord (leptomeningeal metastasis). It may help control disease in that area while aiming to better protect surrounding healthy tissue.
Aarhus, AarhusAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT05747625RecruitingPhase 1
PET/CT scan using panitumumab to find head and neck cancer spread
This Phase 1 study tests a new way to use a scan (PET/CT) with a drug called panitumumab to help spot where head and neck squamous cell cancer has spread. It may help doctors better target treatment by finding metastases earlier or more clearly.
Nashville, TennesseeAges 19 years+ - NCT05748093RecruitingPhase 4
Boost osimertinib levels using cobicistat to improve value
This study tests whether adding cobicistat can increase and stabilize the effect level of osimertinib while keeping treatment cost-effective. You would take osimertinib 80 mg daily, with blood tests to see how your body processes the drug.
Maastricht, LimburgAges 18 years+ - NCT05748197RecruitingPhase 1
Study of ADCLEC.syn1 for relapsed or resistant AML
This Phase 1 study tests ADCLEC.syn1, a new treatment made from a patient’s immune cells, in adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see how safe it is and how well it may work, especially after standard treatments have not helped.
Basking Ridge, New JerseyAges 18 years+ - NCT05748145RecruitingPhase 2
Metronidazole before colon cancer surgery to reduce recurrence risk
This Phase 2 study tests whether taking metronidazole, an antibiotic, before surgery for colorectal cancer can improve outcomes. Participants take it before their planned operation, and doctors study the cancer tissue and related markers to see if it helps.
Bellinzona, Canton TicinoAges 18 years+ - NCT05748210Recruiting
App to help children’s cancer after-treatment symptoms
This study tests a smartphone/tablet app that helps children who have finished cancer treatment and their caregivers manage early symptoms that may come back after treatment. It may help families track symptoms and get supportive guidance during the early survivorship period.
Hong KongAges 9–16 - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT05749887Recruiting
Salvage surgery after chemo-radiation for cervical cancer
This trial studies whether doing surgery after standard chemo-radiation can help control cervical cancer that may still be present. It may be an option if your biopsy or PET-CT scan suggests residual tumor in the cervix and/or nearby pelvic lymph nodes.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT05751343RecruitingPhase 2
Test atezolizumab and bevacizumab with liver cancer procedures
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
Guangzhou, GuangdongAges 18–75 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05752136RecruitingPhase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05752448Recruiting
Care plan support for women after ovarian cancer treatment
This trial looks at survivorship care—how to help women after ovarian cancer treatment. It may improve follow-up planning and support during the first months after treatment ends.
Dallas, TexasAges 18 years+ - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT05752604Recruiting
Study of treatments and factors in thyroid cancer
This study looks at thyroid cancer and how standard treatments and other health details relate to outcomes. You might be eligible if you have thyroid cancer and can participate by giving informed consent.
MilanAges Any age - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05753618RecruitingPhase 4
Skipping growth-factor shots during breast cancer chemotherapy
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
Kingston, OntarioAges 18 years+ - NCT05754580Recruiting
Boost radiation for intermediate or higher-risk prostate cancer
This study tests a stronger, focused radiation plan for intermediate to higher-risk prostate cancer. It combines a high-dose internal radiation “boost” with external radiation to try to improve cancer control while keeping side effects manageable.
Omaha, NebraskaAges 19 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,689 recruiting oncology studies from the U.S. registry right now, out of 31,955 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.